A simple finger prick could replace blood draws for cancer drug monitoring

NCT ID NCT05598788

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a tiny finger-prick blood sample can accurately measure levels of nine oral cancer drugs, compared to standard blood draws. Researchers will enroll 160 patients taking one of these drugs. If the microsampling method works, it could offer a less invasive way to personalize dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If validated, this finger-prick method could make it easier and less painful to monitor drug levels in cancer patients, potentially improving personalized dosing.

What could go wrong

This is an observational validation study, not a treatment trial. The microsampling technique may not prove accurate enough for routine clinical use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLOOD CONCENTRATIONS OF NINE ANTI-CANCER DRUGS : AXITINIB, OLAPARIB, REGORAFÉNIB, CABOZANTINIB, NIRAPARIB, TALAZOPARIB, PALBOCICLIB, ABEMACICLIB, TUCATINIB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Eugène Marquis Unicancer

    Rennes, 35000, France

  • Institut de cancérologie Strasbourg Europe

    Strasbourg, 67033, France

  • Rennes University Hospital

    Rennes, 35000, France